Partnering for Therapeutics Discovery

National Institutes of Health, Bethesda, Maryland, USA.
Clinical Pharmacology &#38 Therapeutics (Impact Factor: 7.9). 11/2012; 93(1). DOI: 10.1038/clpt.2012.188
Source: PubMed


The Discovering New Therapeutic Uses for Existing Molecules pilot program, led by the National Center for Advancing Translational Sciences (NCATS), uses innovative strategies such as crowdsourcing and template agreements to match ­researchers with a selection of molecular compounds from industry in order to test ideas for new therapeutic uses. Awardees will have the opportunity to validate and de-risk the targets of already well-developed compounds with the ultimate goal of identifying promising new treatments for patients.Clinical Pharmacology & Therapeutics (2013); 93 1, 24-25. doi:10.1038/clpt.2012.188

3 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Enabling science and information technologies has catalyzed a surge of biological, clinical, demographic, health services, and comparative-effectiveness data. While accelerating the deconvolution of complex pathophysiological, medical, social, and environmental networks and systems, these platforms have produced informational quanta devoid of contextualization. Therapeutic innovation is thus now challenged with moving beyond knowledge generation and curation to integrated solution-seeking paradigms that organize functionally related information, producing system-level insights into health and disease for optimized patient-centered outcomes. This annual issue on therapeutics innovations highlights emerging considerations for the generation and hierarchical organization of scientific and clinical information and its translation to advancing next-generation disease management.
    Clinical Pharmacology &#38 Therapeutics 01/2013; 93(1):3-7. DOI:10.1038/clpt.2012.208 · 7.90 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Research emphasis on rare diseases and orphan products remains a major focus of the research Institutes and Centers of National Institutes of Health (NIH). NIH provides more than USD 31 billion annually in biomedical research and research support. This research is the basis of many of the health advances in rare and common diseases. Numerous efforts and a major emphasis by the public and private sector initiatives have resulted in an increase of interventions and diagnostics for rare diseases. Newer translational research programs provide a more systematic and coordinated approach to rare diseases research and orphan products development. The approach that is offered requires extensive public-private partnerships with the pharmaceutical industry, contract research organizations, philanthropic foundations, medical and scientific advisory boards, patient advocacy groups, the academic research community, research and regulatory scientists, government funding agencies, and the public. Each program is unique and requires lengthy planning and collaborative efforts to reach programmatic goals. © 2013 S. Karger AG, Basel.
    Public Health Genomics 04/2013; 16(6):259-67. DOI:10.1159/000355929 · 2.21 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: Precompetitive public-private partnerships (PPPs) have the potential to improve psychiatric drug discovery by addressing gaps in the research and development pipeline such as the identification and validation of new targets, models, biomarkers and disease phenotyping. PPPs are a model to strategically bring together expertise, in-kind support and funding from multiple public and private sector partners. Areas covered: This editorial describes selected case examples of established and emerging public-private consortia in the United States and Europe that provide tools, methods or resources to accelerate central nervous system (CNS) drug discovery. The authors provides a listing of public-private consortia projects that focus on the CNS, the stage of the drug discovery pipeline that they address, diseases, deliverables provided and current consortia partners. Expert opinion: Some of the projects undertaken by PPPs in the area of CNS drug discovery and development are beginning to make tools, resources and data publicly available. Only a few PPPs have delivered enough to extract lessons learned. These include building alignment across a wide group of stakeholders, engaging advocacy groups and funding commitments for a minimum of 5 years.
    Expert Opinion on Drug Discovery 12/2013; 9(1). DOI:10.1517/17460441.2014.867944 · 3.54 Impact Factor